Cargando…
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study
OBJECTIVES: Dabigatran is a direct thrombin inhibitor shown to be an effective alternative to warfarin in patients with non-valvular atrial fibrillation (AF). We evaluated the use of dabigatran in patients with bioprosthetic mitral and/or aortic valve replacement and AF. METHODS: We selected 34 and...
Autores principales: | Durães, André Rodrigues, de Souza Roriz, Pollianna, de Almeida Nunes, Bianca, Albuquerque, Felipe Pinho e, de Bulhões, Fábio Vieira, de Souza Fernandes, Andre Mauricio, Aras, Roque |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875919/ https://www.ncbi.nlm.nih.gov/pubmed/26892845 http://dx.doi.org/10.1007/s40268-016-0124-1 |
Ejemplares similares
-
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: Protocol
por: Duraes, Andre Rodrigues, et al.
Publicado: (2014) -
Antithrombotic Strategy in the Three First Months following Bioprosthetic
Heart Valve Implantation
por: Durães, Andre R., et al.
Publicado: (2013) -
Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study
por: Durães, André R., et al.
Publicado: (2018) -
Evaluation of variables responsible for hospital mortality in patients
with rheumatic heart disease undergoing double valve replacement
por: Fernandes, André Maurício Souza, et al.
Publicado: (2014) -
Sutureless bioprosthesis for aortic valve replacement: Surgical and clinical outcomes
por: Ferreira, Ricardo, et al.
Publicado: (2022)